Brief: Transgene, NEC Announce Positive Preliminary Data From TG4050 Studies

Transgene SA

22/11/2021 16:51

Nov 22 (Reuters) - TRANSGENE SA  TRNG.PA :
    * TRANSGENE AND NEC ANNOUNCE POSITIVE PRELIMINARY DATA FROM
PHASE
I STUDIES OF TG4050, A NOVEL INDIVIDUALIZED NEOANTIGEN CANCER
VACCINE
    * TG4050 WAS WELL TOLERATED, WITH NO RELATED SERIOUS ADVERSE
EVENTS REPORTED ACROSS TWO STUDIES TO DATE
    * TG4050 INDUCED ROBUST ANTI-TUMOR CELLULAR IMMUNE RESPONSES
AGAINST MULTIPLE NEOANTIGEN TARGETS IN ALL EVALUABLE PATIENTS
(4/4)
    * TG4050 MONOTHERAPY WAS ALSO ASSOCIATED WITH FIRST SIGNS OF
CLINICAL ACTIVITY
    * TG4050 WAS WELL TOLERATED, WITH NO RELATED SERIOUS ADVERSE
EVENTS REPORTED ACROSS TWO STUDIES TO DATE.
    * ADDITIONAL PATIENTS ARE BEING ENROLLED, WITH AIM TO TREAT
UP TO
43 PATIENTS ACROSS TWO MULTICENTER TRIALS (USA, UK, FRANCE)
    * FURTHER DATA WILL BE RELEASED AT A MAJOR ONCOLOGY
CONFERENCE
OVER COMING MONTHS AND WILL PROVIDE INSIGHT NEEDED TO PREPARE
PHASE II TRIALS

Source text for Eikon:  ID:nBw2YMGH0a 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))